Posted by Michael Wonder on 11 Apr 2022
Poxel announces PXL770 awarded FDA fast track designation for X-linked adrenoleukodystrophy
11 April 2022 - Poxel is pleased to announce that the U.S. FDA has granted fast track designation to PXL770 for the treatment of patients with adrenomyeloneuropathy, the most common form of X-linked adrenoleukodystrophy.
PXL770 is a novel, first-in-class direct adenosine monophosphate-activated protein kinase activator that is preparing to enter into a Phase 2a clinical proof of concept biomarker study midyear, subject to additional financing.
